BPC-157 / TB-500 ("Wolverine Stack").
Two of the most studied recovery peptides combined in one protocol for soft-tissue support.
500 mcg / 500 mcg oral capsule · 3 mg / 3 mg per mL injectablePricing is shown after your free assessment, before you commit.
Free to start. No card required.
Reviewed by Lumora clinical team (Licensed provider network)Mixed evidenceSource: Client-approved product catalog; provider review required
Evidence, regulatory status, and fit vary by medication, formulation, route, and individual history.
Is this for you?
This is for you if
- Patients with joint pain, tendon issues, or lingering injuries
- Active patients with repeat-strain injuries
- Patients recovering from surgery or intense training
- Patients wanting a streamlined two-peptide recovery protocol
This isn't for you if
Investigational. Components are dispensed through 503A compounding pharmacies. Not appropriate during pregnancy, breastfeeding, or with active malignancy. TB-500 is on the WADA prohibited list for competitive athletes.
BPC-157 / TB-500 ("Wolverine Stack")
This combination — informally called the "Wolverine Stack" — pairs BPC-157, a peptide derived from a protective sequence in human gastric juice, with TB-500, a synthetic fragment of Thymosin Beta-4. The two complement each other across different stages of the body's repair process.
Mechanism and fit.
BPC-157 reduces inflammation, supports angiogenesis (new blood vessel formation), and strengthens the gut lining that contributes to systemic recovery. TB-500 promotes cell migration and actin signaling — the structural protein involved in muscle and connective-tissue repair. Together they support recovery in tendons, ligaments, fascia, and muscle that traditionally heal slowly.
Who this is typically for.
- Patients with joint pain, tendon issues, or lingering injuries
- Active patients with repeat-strain injuries
- Patients recovering from surgery or intense training
- Patients wanting a streamlined two-peptide recovery protocol
What patients
most often ask.
Why combine them instead of using one?
BPC-157 and TB-500 work on different parts of the healing process. BPC-157 calms inflammation and supports baseline tissue repair; TB-500 drives circulation and cell migration in slow-healing tissue. Patients with stubborn or complex injuries often respond better to the combination.
Oral or injectable?
Oral capsules suit gut-focused or whole-body protocols. Injectable is typically used near a specific area of focus, or systemically for faster effect. Your provider will recommend the right form for your goals.
Who this is typically for.
These are common fit patterns from the approved catalog. Your provider determines whether treatment is appropriate.
- <ul><li>Patients with joint pain, tendon issues, or lingering injuries</li><li>Active patients with repeat-strain injuries</li><li>Patients recovering from surgery or intense training</li><li>Patients wanting a streamlined two-peptide recovery protocol</li></ul>
How this option
is evaluated.
The plan is provider-determined after reviewing your assessment and safety factors.
- DosingOnce daily, typically 5 days on / 2 days off — oral capsule or subcutaneous injection per provider direction.
- Typical duration6–8 weeks per cycle; longer for chronic issues under provider guidance.
- Safety and eligibilityYour provider reviews contraindications, medication interactions, goals, and safety factors before prescribing.
- A licensed provider reviews your assessment before any treatment is recommended.
- You see full pricing - visit fees, medication, labs, follow-up - before you commit.
- Your plan can be adjusted, paused, or stopped based on response and safety. Your clinician is reachable - not a chatbot.
- Compounded medications are not FDA-approved and are dispensed only when prescribed by a licensed provider.
Start with
provider review.
If you are considering BPC-157 / TB-500 ("Wolverine Stack"), the first step is a free assessment. A provider determines whether it fits your goals and medical history.
A provider determines whether treatment is clinically appropriate.